Canada Pension Plan Investment Board decreased its position in shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) by 71.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 46,600 shares of the biotechnology company’s stock after selling 115,800 shares during the quarter. Canada Pension Plan Investment Board’s holdings in ZIOPHARM Oncology were worth $286,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its position in ZIOPHARM Oncology by 8.2% in the second quarter. The Manufacturers Life Insurance Company now owns 104,447 shares of the biotechnology company’s stock worth $649,000 after acquiring an additional 7,946 shares during the period. State Street Corp raised its position in shares of ZIOPHARM Oncology by 12.8% during the 2nd quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock valued at $28,342,000 after purchasing an additional 517,057 shares during the period. Tudor Investment Corp ET AL raised its position in shares of ZIOPHARM Oncology by 390.4% during the 2nd quarter. Tudor Investment Corp ET AL now owns 63,304 shares of the biotechnology company’s stock valued at $394,000 after purchasing an additional 50,395 shares during the period. Voya Investment Management LLC raised its position in shares of ZIOPHARM Oncology by 21.9% during the 2nd quarter. Voya Investment Management LLC now owns 60,782 shares of the biotechnology company’s stock valued at $378,000 after purchasing an additional 10,913 shares during the period. Finally, Parametric Portfolio Associates LLC increased its holdings in ZIOPHARM Oncology by 6.0% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 85,837 shares of the biotechnology company’s stock valued at $534,000 after acquiring an additional 4,826 shares during the last quarter. Hedge funds and other institutional investors own 40.25% of the company’s stock.
A number of analysts have issued reports on the stock. ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, August 28th. BidaskClub cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. HC Wainwright reissued a “buy” rating and issued a $9.50 price objective on shares of ZIOPHARM Oncology in a research note on Tuesday, November 7th. Finally, Zacks Investment Research raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research note on Friday, November 10th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $12.58.
ZIOPHARM Oncology Inc. (ZIOP) traded up $0.34 during trading hours on Thursday, hitting $4.34. 2,250,398 shares of the stock traded hands, compared to its average volume of 1,387,043. ZIOPHARM Oncology Inc. has a twelve month low of $3.90 and a twelve month high of $7.88.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. The company’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.11) EPS. sell-side analysts expect that ZIOPHARM Oncology Inc. will post -0.54 earnings per share for the current year.
In related news, CEO Laurence James Neil Cooper bought 6,440 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were bought at an average price of $4.68 per share, with a total value of $30,139.20. Following the transaction, the chief executive officer now owns 1,083,731 shares in the company, valued at $5,071,861.08. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.40% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This story was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2017/12/07/canada-pension-plan-investment-board-cuts-stake-in-ziopharm-oncology-inc-ziop-updated-updated.html.
ZIOPHARM Oncology Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.